Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies

George Robinson,[1,2] Ines Pineda-Torra,[3] Coziana Ciurtin,[1,2] and Elizabeth C. Jury[1]

[1]Centre for Rheumatology Research, [2]Centre for Adolescent Rheumatology Research, and [3]Centre for Cardiometabolic and Vascular Science, Division of Medicine, University College London, London, United Kingdom.

Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus. However, conventional therapies with low target specificity can have effects on cell metabolism that are less predictable. A key example is lipid metabolism; current therapies can improve or exacerbate dyslipidemia. Many conventional drugs also require in vivo metabolism for their conversion into therapeutically beneficial products; however, drug metabolism often involves the additional formation of toxic by-products, and rates of drug metabolism can be heterogeneous between patients. New therapeutic technologies and research have highlighted alternative metabolic pathways that can be more specifically targeted to reduce inflammation but also to prevent undesirable off-target metabolic consequences of conventional antiinflammatory therapies. This Review highlights the role of lipid metabolism in inflammation and in the mechanisms of action of AIRD therapeutics. Opportunities for cotherapies targeting lipid metabolism that could reduce immunometabolic complications and potential increased cardiovascular disease risk in patients with AIRDs are discussed.

Introduction

The inflammation associated with autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), is dependent on multiple immune cell subsets within disease-specific settings, each having different metabolic demands (1). For example, effector T cells are dependent on glycolytic metabolism for their growth and effector functions, whereas regulatory T cells utilize lipids via mitochondrial β-oxidation and the generation of ATP through oxidative phosphorylation (OXPHOS) (2). Naive B cells are maintained in a reduced metabolic state, while their activation relies on metabolic programming toward OXPHOS (3). Similarly, during inflammation, inflammatory M1 macrophages use glycolysis, whereas more antiinflammatory M2 macrophages typically use β-oxidation (4). Autoinflammatory responses in AIRDs have high energy demands and involve elevated lipogenesis, glucose and glutamine metabolism, and a switch toward cellular glycolysis from OXPHOS for energy metabolism. For example, hypoxia in the RA synovium induces chronic T cell mitochondrial hyperpolarization associated with increased glucose metabolism and ATP synthesis, and in SLE patients and lupus-prone mice, chronically activated T cells have increased mitochondrial glucose oxidation and hyperpolarization, as reviewed previously (1, 5). Many of the current therapies for AIRDs influence lipid metabolic pathways to exert their therapeutic benefit; furthermore, lipid metabolism could play a role in the pathogenesis of AIRDs and associated comorbidities. This Review discusses lipid metabolism in inflammation and mechanisms of action of AIRD therapeutics, addresses the on- and off-target metabolic effects induced by these therapies, and highlights opportunities for cotherapies targeting lipid metabolism that could benefit patients, with a focus on cardiovascular disease (CVD) risk, an important comorbidity in patients with AIRDs.

Lipid metabolic pathways in inflammation

Lipid metabolism is a crucial aspect of cellular metabolism and effective immune responses; lipids derived from both de novo biosynthesis and exogenous sources are essential for fuel and growth and as membrane components, and mediate cell signaling (6), as summarized in Figure 1. Aspects of lipid metabolism that could contribute to disease pathogenesis and associated comorbidities in patients with AIRDs and serve as therapeutic targets are outlined below.

Immune cell lipid membranes and dyslipidemia

Immune cell plasma membranes comprise a phospholipid bilayer containing highly ordered areas enriched in glycosphingolipids and cholesterol, called lipid rafts. Immune cell surface receptors (including T cell and B cell receptors and costimulatory molecules) reside within lipid rafts and facilitate appropriate cell signaling in response to antigen or other cellular ligands (refs. 7–9 and Figure 1, A–C). Lipid rafts are altered in SLE, in which an increase in both cell membrane glycosphingolipids and cholesterol attributable to increased cellular lipid synthesis is associated with increased T cell and B cell receptor signaling and ultimately activation and inflammation (10, 11). Circulating lipids also play a role in immune cell function, through lipid uptake from VLDL or LDL via the VLDL or LDL receptor (VLD-LR or LDLR), respectively, or from HDL via scavenger receptor class B type I (SR-BI) and CD36; or through lipid efflux to HDL or apolipoprotein A1 via ATP-binding cassette transporter A1 (ABCA1) and ABCG1. Both uptake and efflux influence cellular lipid burden and function (ref. 12 and Figure 1C). This is of particular importance

Figure 1. Summary of lipid metabolism pathways important for inflammation. (i) Lipid rafts: cholesterol- and glycosphingolipid (GSL)-enriched cell signaling platforms. (ii) De novo GSL biosynthesis: differential expression influences immune receptor–mediated signaling and cell function. (iii) Intracellular cholesterol is regulated by liver X receptor (LXR) and sterol regulatory element–binding protein 2 (SREBP-2) (see v). LXR activation by oxysterols induces cholesterol efflux (ABCA1, ABCG1) and reduces lipid uptake (LDLR, VLDLR, SR-BI, CD36). Niemann-Pick type C1 (NPC1) and NPC2 regulate lysosomal/late endosomal trafficking/recycling of intracellular lipids. SREBP-2 opposes LXR and promotes cholesterol biosynthesis and uptake (*HMGCoAR*, *LDLR*). (iv) Nutrition influences fatty acid composition and metabolism. Fatty acids are metabolized to produce energy (ATP) by mitochondrial β-oxidation and TCA. Monounsaturated fatty acids (MUFAs) are synthesized via acetyl-CoA, fatty acid synthase (FASN), and stearoyl-CoA desaturase (SCD). Polyunsaturated fatty acids (PUFAs), diet-derived or biosynthesized in vivo, influence arachidonic acid (AA) metabolism. PUFAs are precursors to triglycerides, phospholipids in plasma membrane, second messengers, hormones, and ketone bodies. Prostaglandins (PGs) are produced following AA release from membrane phospholipids. Downstream PG signaling and eicosanoids have direct metabolic effects on immune cells via PPARs, mediating antiinflammatory effects and modulating LXRs (see v). Omega-3 (ω-3) PUFAs are enzymatically converted to antiinflammatory resolvins (specialized pro-resolving mediators [SPMs]). (v) Lipid metabolism activates transcription factors and influences inflammation via multiple mechanisms (see text). (vi) PUFA phospholipid peroxidation is induced by iron overload and ROS. Products of lipid peroxidation are eliminated via glutathione peroxidase-4 (GPX4); clearance defects induce cell membrane damage and ferroptosis. Sphingosine 1-phosphate (S1P) is derived from membrane phospholipids; activation via binding to S1P receptors (S1PR1–5) initiates immune cell localization to inflammatory sites and T cell differentiation. §, †, and # indicate processes activating LXR, SREBP2, or PPARs, respectively. Other abbreviations: B4GALT5, β-1,4-galactosyltransferase-5; Cer, ceramide; CS, ceramide synthase; DHCR24, 24-dehydrocholesterol reductase; FABPs, fatty acid–binding proteins; GlcCer, glucosylceramide; GM, GM1 ganglioside; GSH, glutathione; HMGCS, 3-hydroxy-3-methylglutaryl–CoA synthase-1; LacCer, lactosylceramide; ox, oxidized; Sph, sphingosine; SphK1, sphingosine kinase-1; SPP1, S1P phosphohydrolase-1; SR-BI, scavenger receptor class B type I; ST3Gal5, ST3 β-galactoside α-2,3-sialyltransferase-5; UGCG, UDP-glucose ceramide glucosyltransferase.

in autoimmunity, where dyslipidemia and cardiovascular complications are common (13). Many studies report altered lipoprotein metabolism in AIRDs. This includes reduced serum total cholesterol, triglycerides, and LDL-cholesterol (LDL-C) in patients with untreated RA that increase when patients are treated (the so-called lipid paradox in RA; ref. 14), and elevated LDL-C and medium-chain/free fatty acids and reduced HDL and long-chain fatty acids in SLE (15–18). Interestingly, a dysfunctional proinflammatory HDL, lacking the antioxidant capacity of conventionally cardioprotective HDL, is described in 48.2% of women with SLE (15), and in

patients with active RA (19), highlighting the prevalence of this form of HDL in AIRDs that is rarely measured and could be associated with elevated cardiovascular risk.

Pro- and antiinflammatory lipid metabolism

Proinflammatory lipids including eicosanoids contribute to some of the typical clinical symptoms associated with many AIRDs, such as joint pain, stiffness, and swelling (ref. 20 and Figure 1D). Eicosanoids are produced following the phospholipase A_2–mediated release of arachidonic acid from membrane phospholipids (21). Arachidonic

acid (an essential polyunsaturated omega-6 fatty acid) is subsequently converted into active metabolites by cyclooxygenase (COX), lipoxygenase, and cytochrome p450 (CYP) enzymes (20, 22). Downstream eicosanoid signaling can have a direct metabolic effect on immune cell subsets via the modulation of PPARs, nuclear hormone receptors that mediate antiinflammatory effects and modulate liver X receptors (LXRs), regulators of cholesterol homeostasis (23). Prostaglandin signaling can either stimulate (prostaglandin D_2) or inhibit (prostaglandins $F_{2\alpha}$ and E_2) the antiinflammatory ability of PPARγ to antagonize NF-κB in multiple immune cells, including T cells, B cells, macrophages, and dendritic cells (refs. 24, 25, and Figure 1E). PPARγ has been detected in macrophage-rich regions of human atherosclerotic plaques, where it controls lipid homeostasis and inhibits activation induced by proinflammatory cytokines (26). Although the functions of PPARs are tissue specific, some functions affecting lipoprotein metabolism include induction of lipolysis, reduced cellular triglyceride synthesis and VLDL production, enhanced intracellular LDL catabolism, and increased HDL production (27).

More recently, lipid metabolites termed specialized pro-resolving mediators (SPMs) have been shown to mediate resolution of inflammation and the restoration of tissue homeostasis. SPMs (including lipoxins, resolvins, and protectins) are produced by immune cells from the enzymatic conversion of omega-3 fatty acids and could be dysregulated in the context of AIRDs (refs. 20, 28, and Figure 1D). SPM levels correlate with decreased joint pain in RA patients (29) and are reduced in experimental models of RA with non-resolving joint inflammation (30). SPMs and other metabolites could also serve as biomarkers for predicting drug efficacy. A machine learning study in RA identified that peripheral blood SPM levels correlated positively with antirheumatic drug responsiveness at 6 months; notably decreased SPM concentrations were seen in nonresponders (31).

Sphingosine 1-phosphate
Sphingosine 1-phosphate (S1P), derived from membrane phospholipids, exerts its effect by binding GPCRs (S1P receptors) (Figure 1F). S1P binding initiates multiple cellular and physiological events, including immune cell localization to inflammatory sites, trafficking of lymphocytes to and from secondary lymphoid organs, and the regulation of T cell differentiation (between proinflammatory Th17 cells and Tregs) (32). Interestingly, HDL is an important S1P chaperone, and cellular uptake of HDL-S1P by SR-BI facilitates binding to S1P receptors with subsequent signaling in a cell-specific manner (33). Targeting of S1P receptors is an effective therapy to inhibit lymphocyte trafficking in patients with multiple sclerosis, and clinical trials are exploring similar therapies in AIRDs (34).

Ferroptosis
Ferroptosis is a form of regulated cell death driven by iron-dependent lipid oxidation (Figure 1F). Peroxidation of phospholipids containing polyunsaturated fatty acids is mediated by iron overload (free iron and iron-dependent lipoxygenases) and ROS. Under normal homeostatic conditions, cells can eliminate products of lipid peroxidation via several complex mechanisms (including glutathione peroxidase 4, an inhibitor of phospholipid peroxidation); however, in numerous conditions, including inflammation, these mechanisms are defective, leading to cell membrane damage and ferroptosis (35). Notably, increased ROS levels induced during inflammation in AIRDs could

contribute to increased ferroptosis (36). Higher concentrations of free iron and other iron-binding proteins in synovial fluid and infusion of iron-dextran increase lipid peroxidation, decrease red cell glutathione, and exacerbate RA synovitis (36). In SLE, increased dietary iron and iron infusion also exacerbate disease activity (37). However, it remains to be confirmed whether inhibiting ferroptosis could be beneficial in AIRDs (36, 37).

Conventional antiinflammatory therapies
Many of the antiinflammatory therapies used to treat AIRDs influence multiple metabolic pathways, as summarized in Figure 2 and Tables 1–4; the effects of these drugs on lipid metabolism are described below.

Nonsteroidal antiinflammatory drugs
Eicosanoids are drivers of inflammation in AIRDs and are major targets of antiinflammatory therapies, including nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis through the inhibition of COX enzymes (ref. 20 and Table 1). NSAIDs include both nonselective NSAIDs (e.g., aspirin, ibuprofen, diclofenac, phenylbutazone, mefenamic acid) and selective COX-2 inhibitors (e.g., celecoxib and rofecoxib) (38). The antiinflammatory potency of COX-2 inhibitors is higher than that of nonselective NSAIDs, which is reflected in better clinical outcomes in RA and other types of inflammatory arthritis (39, 40). While all COX inhibitors are effective at treating inflammation, their side effects include cardiovascular, gastrointestinal, and renal complications (41). Of relevance to AIRDs is the association of selective COX-2 inhibition with increased risk of thrombotic events. Thromboxane A_2 is an eicosanoid lipid mediator derived mainly from activated platelets, which constitutively express only COX-1. Thromboxane A_2 induces vasoconstriction, endothelial adhesion molecule expression, and platelet aggregation and production among other effects, and is elevated in cardiovascular and inflammatory diseases; whereas COX-2 mediates the production of prostacyclin, which mediates vasodilation, inhibits platelet aggregation, and restrains the cardiovascular effects of thromboxane A_2. Thus, both thromboxane A_2 and prostacyclin are important mediators of CVD risk (42). CVD risk may also be associated with localized alterations in prostaglandin metabolism and PPARγ activity where the COX isoforms are coexpressed in atherosclerotic plaques (43, 44). Consequently, while COX-1 inhibition protects against atherosclerotic progression (for example, low-dose aspirin inhibits platelet-derived thromboxane A_2), selective COX-2 inhibitors block cardioprotective prostacyclin and are associated with increased CVD risk (45). In clinical practice, individual CVD risk can be predicted using validated clinical scores; however, the complexity and heterogeneity of therapeutic responses and their direct or indirect impact on lipid metabolism could influence long-term outcomes (45).

Disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs (DMARDs) inhibit inflammatory immune cell responses through various mechanisms (Figure 2 and Tables 1 and 2) and have been used reliably to treat AIRDs for many years. However, DMARD use can be associated with dyslipidemia, driven either by the impact of drugs on the liver or by the toxic side effects of drug metabolites (46, 47). More recent insights

Figure 2. Summary of the mechanisms of action of current therapies used in AIRDs. Schematic representation summarizing the key mechanistic pathways affected by both traditional and modern therapies used to treat AIRDs, including disease-modifying antirheumatic drugs (DMARDs), target synthetic DMARDs (tsDMARDs), nonsteroidal antiinflammatory drugs (NSAIDs), steroids, and biologics. The majority of these therapeutics result in the modification of immune functions and metabolic pathways through alterations in gene transcription. These pathways provide insight into opportunities for cotherapies to prevent off-target immunometabolic effects. AA, arachidonic acid; Aza, azathioprine; CP, cyclophosphamide; GF, growth factor; GR, glucocorticoid receptor; HCQ, hydroxychloroquine; NF-κB, nuclear factor NF-κB (p50/p52/RelA/RelB/); IκB, inhibitor of κB; MAP2/3K, mitogen-activated protein 2-kinase or 3-kinase; MMF, mycophenolate mofetil; MTX, methotrexate; NFAT, nuclear factor of activated T cells; PG, prostaglandin; R, receptor; RXR, retinoid X receptor; SASP, sulfasalazine; SYK, spleen-associated tyrosine kinase; TCR, T cell receptor.

into the lipid metabolic pathways influenced by many DMARDs have provided new understanding of their antiinflammatory and immunomodulatory properties.

Prednisolone. Prednisolone (glucocorticoid steroid hormone) effectively reduces inflammation, but long-term use has many side effects, including hypertension, obesity, dyslipidemia, and atherosclerosis (refs. 48–50 and Table 1). The mechanisms underpinning these effects could be associated with the promotion of fatty acid synthase and acetyl-CoA carboxylase activity, as well as inhibition of fatty acid β-oxidation by blocking of acyl-CoA dehydrogenase activity (ref. 51 and Figure 1D). Together, these processes result in hepatic fat accumulation and increased circulating triglycerides and VLDL. There is evidence that low-dose prednisolone attenuates postprandial suppression of lipid oxidation in patients with RA (52). Prolonged prednisolone use exacerbates dyslipidemia despite the preferential antiinflammatory effects of treatment (53, 54), although some studies show that RA patients treated with prednisolone can have increased levels of HDL (55). Hepatic lipid accumulation induced by prednisolone can impair insulin signaling through increased activation of MAPK signaling (51). As with many therapies, it has been

important to measure these adverse metabolic effects against clinical benefits (48). Baseline lipid profile is considered when patients are started on corticosteroids, but the clinical need for treatment likely takes priority. If prednisolone treatment is of short duration (e.g., acute flare of gout, bridging therapy in RA) (56), then dyslipidemia is not clinically managed in any particular way. However, long-term prednisolone treatment requires monitoring of lipid profile as indicated in various guidelines and as part of CVD risk management recommendations (53, 57).

Hydroxychloroquine. Despite the widespread use and efficacy of hydroxychloroquine in the treatment of AIRDs (58), its mechanism of action is relatively unclear. It has beneficial effects on lipid and glucose metabolism but also exerts multiple other immunomodulatory actions (ref. 59 and Table 1). The atheroprotective role of hydroxychloroquine is likely due to both its antiinflammatory and its lipid-modifying effects. Hydroxychloroquine is protective against endothelial cell damage, hypertension, and thrombosis (CVD risk factors) via the inhibition of endothelin-1 (a potent vasoconstrictor), downregulation of proinflammatory cytokines such as TNF-α, and reduced levels of proinflammatory ROS, which inhibit platelet

Table 1. Mechanisms of action of current conventional therapies used in AIRDs (part 1)

Drug	Mechanisms/effects	Effects on lipid metabolism	Refs.
NSAIDS	Inhibit COX-1 and COX-2 enzymes, which catalyze production of lipid-based metabolic mediators (eicosanoids), e.g., prostaglandins and leukotrienes. Prostaglandins are unsaturated fatty acids that have diverse effects, including vasodilation, pain, platelet aggregation, and stomach acid secretion, and contribute to clinical symptoms such as joint pain, stiffness, and swelling. COX-1 is ubiquitously expressed and has important homeostatic functions. COX-2 is upregulated by proinflammatory cytokines via NF-κB signaling at sites of inflammation and is the primary source of prostaglandin production in AIRDs including RA and SLE.	Inhibits the production of lipid-based metabolic mediators (eicosanoids), including prostaglandins and leukotrienes.	20, 45, 190–193
Prednisolone	Reduces inflammation and is a cornerstone treatment for many AIRDs. Lipophilic and binds to GCRs in the cell cytoplasm. Ligand-bound GCRs are dissociated from chaperone proteins, where they inhibit NF-κB activation and the transcription of inflammatory genes. Activated GCRs also bind to and inhibit the activity of JNK, and components of the T cell receptor signaling pathway, thereby reducing inflammation. Ligand-bound GCRs translocate to the nucleus, bind to glucocorticoid response elements, induce the transcription of antiinflammatory genes, and inhibit proinflammatory genes by binding to upstream genomic regions. Can induce hyperglycemia and increase the risk of diabetes through the transcriptional induction of phosphoenolpyruvate carboxykinase and glucose 6-phosphatase expression by GCR promoter binding. These enzymes decarboxylate oxaloacetate to phosphoenolpyruvate and hydrolyze glucose 6-phosphate into free glucose, respectively, and both promote hyperglycemia.	Effects of long-term use include hypertension, obesity, dyslipidemia, and atherosclerosis. Promotes fatty acid synthase and acetyl-CoA carboxylase activation and inhibition of fatty acid β-oxidation by blocking acyl-CoA dehydrogenase activity. Induces hepatic fat accumulation and increased circulating triglycerides and VLDL.	48–51, 194–196
Hydroxychloroquine	A lipophilic, weak base that accumulates in acidic environments including intracellular vesicles (lysosomes, endosomes, autophagosomes) and inflamed tissue. Alters lysosomal function and autophagy by inhibiting endosomal trafficking, endosome-lysosome fusion, and lysosomal protease activity via changes in endosomal pH. Inhibits antigen presentation by altering degradation of phagocytosed peptides and inhibiting MHC class II antigen presentation. Slows insulin metabolism and reduces hyperglycemia in patients with non–insulin-dependent diabetes. Prevents endosomal TLR signaling, via steric binding to ligands (e.g., TLR7 and TLR9 binding their respective ligands RNA and DNA). Inhibits proinflammatory cytokine production.	Protective against endothelial cell damage, hypertension, and thrombosis via the inhibition of endothelin-1 (a potent vasoconstrictor), downregulation of proinflammatory cytokines such as TNF-α, and reduced levels of proinflammatory ROS, which inhibit platelet aggregation. Reduces atherogenic triglycerides and total cholesterol and LDL-C and increases HDL-C. Is a substrate for CYP enzymes, associated with the metabolism of many drugs. Binds to sialic acid–containing glycolipids within plasma membrane lipid rafts and inhibits viral uptake. Disrupts lysosomal membranes; therefore, it could modify lipid raft–mediated immune cell signaling.	9, 59–64, 67, 68, 197–201
Calcineurin inhibitors	Inhibit dephosphorylation and nuclear transfer of NFAT, via the cytoplasmic calcium/calmodulin pathway, thereby blocking T cell activation and transcription of proinflammatory genes and IL-2, and upregulation of glucose transporters and glycolytic enzymes that support nutrient supply for T cell proliferation and inflammatory responses. Block NF-κB and MAPK signaling. Significant off-target effects include high renal toxicity (associated with alterations in electrolyte availability including hyperkalemia, metabolic acidosis, hypercalciuria, and hyperuricemia).	Impair endothelial cell function associated with COX-2 inhibition and reduced prostaglandin E_2 production. Dyslipidemia (increased total cholesterol, LDL-C, triglycerides, apolipoprotein B). Reduced hepatic LDL clearance and increased cholesterol biosynthesis via the HMG-CoA pathway mediated by inhibition of 27-hydroxycholesterol, an oxysterol that inhibits cholesterol metabolism via HMG-CoA. Inhibit bile acid synthesis via 26-hydroxylase and could reduce triglyceride degradation by inhibiting lipoprotein lipase activity.	69–72, 74, 75, 202–205

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. GCR, glucocorticoid receptor; HMG-CoA, 3-hydroxy-3-metyhylglutaryl–coenzyme A; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; TLR, Toll-like receptor.

aggregation (60–62). The mechanisms underlying its direct effect on lipid metabolism remain largely unknown. There is evidence that hydroxychloroquine reduces atherogenic triglycerides and total and LDL-cholesterol and increases atheroprotective HDL-cholesterol (63, 64). Hydroxychloroquine is also a substrate for CYP enzymes, which are associated with the metabolism of many drugs; thus, it could interfere with the efficacy of combination therapies that are

metabolized via the CYP pathway, including calcineurin inhibitors (59, 65), or increase the cardiovascular risk in association with various antibiotics (66). Hydroxychloroquine-mediated changes in lipid metabolism could influence immune cell function. Interestingly, research investigating hydroxychloroquine in SARS-CoV-2 infection shows that the drug binds to sialic acid–containing glycolipids within plasma membrane lipid rafts and inhibits viral uptake (67).

It has also been shown to disrupt lysosomal membranes; therefore, hydroxychloroquine could also mediate its effects in AIRDs by modifying lipid raft–mediated immune cell signaling, which can in turn modulate immune cell function (refs. 9, 68, and Figure 1A).

Calcineurin inhibitors. Calcineurin inhibitors (cyclosporin, voclosporin, tacrolimus) block T cell signaling and activation (Table 1) but also have noteworthy off-target effects, including impairment of endothelial cell function associated with COX-2 inhibition and reduced production of prostaglandin E_2 (69) and dyslipidemia (increased total cholesterol, LDL-C, triglycerides, and apolipoprotein B) (70, 71). Various mechanisms could contribute to altered lipid levels, including reduced hepatic LDL-C clearance and increased cholesterol biosynthesis via the HMG-CoA pathway mediated by inhibition of 27-hydroxycholesterol, an oxysterol that inhibits cholesterol metabolism via HMG-CoA (ref. 72 and Figure 1C). Interestingly, voclosporin, recently approved for use in adult lupus nephritis, shows a significant reduction in total cholesterol and LDL-C, potentially due to its superior antiinflammatory properties (73). Cyclosporin also inhibits bile acid synthesis via 26-hydroxylase and could reduce triglyceride degradation by inhibiting lipoprotein lipase activity (71, 74). Thus, although calcineurin inhibitors are favorable in AIRDs, further mechanistic research is required to assess the antiinflammatory benefits against the off-target effects of blocking fundamental metabolic processes.

Mycophenolate mofetil and azathioprine. Mycophenolate mofetil (MMF) and azathioprine inhibit cellular proliferation through inhibition of purine nucleotide synthesis pathways (ref. 75 and Table 2). Mycophenolic acid (the active metabolite of MMF) can also activate PPARγ (76) and increase intracellular lipids including fatty acids, cholesterol, and phosphatidylcholine in vitro (77). Such metabolic dysregulation could contribute to MMF function via disruption of cell signaling and membrane integrity. Another study shows that azathioprine reduced abnormally upregulated cellular cholesterol/lipid biosynthesis and uptake and induced ER stress and apoptosis in glioblastoma; this effect was likely mediated by blocking of EGFR/AKT/SREBP-1 signaling and not via the typical ABCA1-mediated cholesterol efflux through the LXR transcription factor, as neither LXR nor ABCA1 levels were altered by azathioprine (78). Interestingly, small-molecule inhibitors of sterol regulatory element–binding protein (SREBP) such as betulin, in addition to their antitumoral effects (79), can reduce cholesterol and fatty acid biosynthesis and atherogenic hyperlipidemia in animal models, suggesting that azathioprine could have a similar effect (80). SREBP-1 also reduces proinflammatory signaling and modulates macrophage phagocytosis (81, 82), additional pathways that could be affected by the inhibition of this transcription factor.

Methotrexate, sulfasalazine, and leflunomide. Methotrexate suppresses lymphocyte proliferation and cytokine production and increases apoptosis via multiple metabolic pathways (Table 2). Patients with RA have atypically reduced lipid levels considering their increased CVD risk (14); in line with this, recent studies show that methotrexate increases total cholesterol and LDL while reducing CVD risk (83), potentially by restoring normal lipoprotein metabolism (84, 85), although reduced proinflammatory cytokine levels and associated inflammation are also likely to play a role (86). The antiinflammatory mechanisms of sulfasalazine are also thought to have cardioprotective effects (87), potentially mediated by scavenging of oxygen radicals leading to decreased lipid peroxidation, inhibition of arachidonic acid metabolism via COX enzymes that results in reduced platelet aggregation, and inhibition of NF-κB signaling (88–91). Alternatively, sulfasalazine can induce ferroptosis, although it is not established whether this influences drug efficacy (ref. 36 and Figure 1F). Leflunomide, another antiproliferative drug, is known to increase hypertension and thus increase CVD risk, although the mechanism is unknown (ref. 92 and Table 2).

Cyclophosphamide. Cyclophosphamide can reduce LDL and VLDL levels and increase acetate (a lipid metabolism by-product) in lupus nephritis patients (93). However, acrolein, a cyclophosphamide metabolite (Table 1), can result in dose-related cardiotoxicity, which is a limiting factor for cyclophosphamide use (94). Acrolein alters levels of heart fatty acid–binding proteins, which deplete antioxidants and ATP levels through altered mitochondrial β-oxidation, thereby reducing the cellular energy pool. Together, these metabolic changes increase apoptosis in cardiomyocytes and can lead to heart failure and myocardial infarction (94). These off-target metabolic effects require close cyclophosphamide dose monitoring and modification in patients with AIRDs. There are few other reports that cyclophosphamide influences metabolite levels in AIRDs (95).

Target synthetic DMARDs

Target synthetic DMARDs (tsDMARDs) are small-molecule inhibitors used increasingly to treat AIRDs since they are less toxic, have fewer adverse effects, and have increased specificity to proteins and signaling pathways associated with disease pathogenesis (96). An array of tsDMARDs exist targeting key proinflammatory signaling pathways that are stimulated by inflammatory mediators (cytokines, chemokines, growth factors, and antigens), including JAK, MAPK, NF-κB, and spleen-associated tyrosine kinase (SYK)/Bruton's tyrosine kinase (BTK) pathways (refs. 96–98 and Table 3). The full impact of inhibition of these pathways on specific metabolic mechanisms is unclear but likely plays an important role in the performance of specific tsDMARDs. Furthermore, crosstalk between various signaling pathways adds complexity to therapeutic strategies; for example, NF-κB target genes can inhibit MAPK signaling (99).

JAK inhibitors

JAK inhibitors block cell signaling via the JAK/STAT pathway (Table 3) but also have cell metabolic effects (including decreased mitochondrial membrane potential, mitochondrial mass, and ROS and inhibition of metabolic genes in synovial tissue) (100) and modify systemic lipid metabolism. Tofacitinib and baricitinib significantly increased HDL-C and LDL-C compared with baseline and other DMARD treatments alone in randomized controlled trials in RA and SLE (101–106), an effect reversed by statins (107). JAK inhibitors also improve HDL function by increasing the activity of lecithin-cholesterol acyltransferase (LCAT; an enzyme that converts free cholesterol to cholesterol esters and supports cholesterol efflux to lipoproteins), thereby increasing HDL efflux capacity (refs. 103, 106, and Figure 1C). Other effects such as alterations in lipoprotein size and content have been described (103, 108); therefore, these therapies may contribute to drug-induced dyslipidemia and exacerbate the lipid imbalances already associated

Table 2. Mechanisms of action of current conventional therapies used in AIRDs (part 2)

Drug	Mechanisms/effects	Effects on lipid metabolism	Refs.
Mycophenolate mofetil	Inhibits cellular proliferation through inhibition of purine nucleotide synthesis. Metabolized to mycophenolic acid by carboxylesterases via noncompetitive inhibition of inosine monophosphate dehydrogenase, an enzyme responsible for the synthesis pathway of guanine nucleotides. Lymphocytes rely solely on this pathway to generate guanine nucleotides; therefore, reduces DNA synthesis and subsequent proliferation and function in T cells and B cells. Suppresses adhesion molecule expression and production of nitric oxide via iNOS by depleting guanosine 5′-triphosphate in lymphocytes/monocytes.	Mycophenolic acid (the active metabolite mycophenolate mofetil) activates PPARγ and increases intracellular lipids including fatty acids, cholesterol, and phosphatidylcholine in vitro.	75–77, 206–208
Azathioprine	Inhibits leukocyte proliferation via inhibition of purine nucleotide synthesis. Reduces T cell proliferation and NFAT signaling and increases apoptosis. Metabolized into imidazole derivatives (with weak immunomodulatory effects) or 6-mercaptopurine, which is further metabolized into toxic nucleotides (e.g., 6-thioguanosine nucleotides), which inhibit amidotransferase enzymes and purine ribonucleotide interconversion and inhibit leukocyte proliferation.	Inhibits abnormally upregulated cellular cholesterol/lipid biosynthesis and uptake and induced ER stress and apoptosis in glioblastoma via blocking EGFR/AKT/SREBP-1 signaling.	75, 78, 209, 210
Methotrexate	Inhibits purine and pyrimidine synthesis, inhibits lymphocyte proliferation and cytokine production, and increases apoptosis. Folate analog: metabolized into polyglutamates. Methotrexate polyglutamates bind with high affinity to dihydrofolate reductase and other enzymes that require folate cofactors such as AICAR transformylase and thymidylate synthetase, involved in purine and pyrimidine synthesis. Increases extracellular adenosine release. Adenosine has wide-ranging antiinflammatory effects: signaling via adenosine receptors on multiple cell types downregulates production of TNF, IL-6, and IL-18 and inhibits NF-κB signaling. Inhibits production of proinflammatory cytokines by blocking phosphorylation of JAK/STAT. Mediates increased apoptosis via increased ROS production; increases glucose uptake and lipid oxidation indirectly through AMPK activation by AICAR. Protects AIRD patients from metabolic syndrome by improving glucose metabolism.	Increases lipid oxidation indirectly through increased AMPK activation and blocking of PGE2 synthesis via inhibition of COX-2. In RA, increases total cholesterol and LDL while reducing CVD risk, potentially by restoring normal lipoprotein metabolism, which is dysregulated in RA.	83–85, 211–219
Sulfasalazine	Metabolized by bacteria in the colon into its active metabolite 5-aminosalicylic acid, which acts through the lumen to confer its antiinflammatory effects through largely unknown mechanisms, which likely include interference with folate transporters and enzymes in the intestine, scavenging of oxygen radicals, PG inhibition via COX enzymes, and inhibition of NF-κB signaling. Reduces T cell proliferation and IL-2 and IFN-γ production as well as monocyte IL-1 and TNF-α production and B cell and NK cell activity.	Cardioprotective effects potentially mediated via scavenging of oxygen radicals leading to decreased lipid peroxidation; inhibition of arachidonic acid metabolism via COX enzymes, resulting in reduced platelet aggregation; and inhibition of NF-κB signaling. Can induce ferroptosis.	36, 87–91
Leflunomide	Targets immune cell proliferation and activation by inhibiting pyrimidine synthesis. Associated with increased risk of hypertension.	Regulates abnormal expression of lipid rafts in B cells from SLE patients.	220, 221
Cyclophosphamide	Metabolized intracellularly into phosphoramide mustard, which induces apoptosis in proliferating immune cells, and acrolein, which is linked to tissue toxicity. Targets actively proliferating autoimmune lymphocytes, which correlates with clinical improvement/ Phosphoramide mustard forms irreversible inter- and intra-strand DNA cross-links at guanine N-7 positions, inducing cellular apoptosis due to inhibition of DNA replication required for proliferation.	Reduces LDL and VLDL levels and increases acetate (a lipid metabolism by-product) in lupus nephritis. Acrolein induces dose-related cardiotoxicity: alters levels of heart fatty acid–binding proteins, which deplete antioxidants and ATP levels through altered mitochondrial β-oxidation, and reduces the cellular energy pool.	93, 94, 222–225

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; AMPK, 5′-adenosine monophosphate–activated protein kinase; iNOS, inducible nitric oxide synthase; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; PG, prostaglandin; SREBP, sterol regulatory element–binding protein.

with AIRDs. Past trials have highlighted concerns surrounding the risk of arterial and venous thrombotic events with JAK inhibition, and emerging evidence suggests that this risk is dependent on JAK selectivity and is potentially confounded by indication (109, 110). Based on a review of a randomized controlled trial of tofacitinib versus anti-TNF treatment, the Food and Drug Administration issued an urgent revision for all JAK inhibitors to include information about potential increased risks of serious heart-related events, cancer, blood clots, and death. These emerging concerns are mirrored in recommendations to assess the benefits and risks for patients before initiating or continuing JAK inhibitor therapy (111).

Targeting the MAPK pathway
The MAPK pathway, comprising ERK, JNK, and p38 kinase (p38) (112), regulates cellular function via activation of transcription factors (Table 3). Although targeting of MAPKs such as p38 by VX-702 has shown clinical benefit in RA and animal models of SLE, the use of MAPK inhibitors is confounded by the vast and pleiotropic

Table 3. Mechanisms of action of tsDMARDs used in AIRDs

Drug	Mechanisms/effects	Effects on lipid metabolism	Refs.
JAK inhibitors	JAK inhibitors competitively bind to JAK ATP-binding sites and suppress JAK enzyme activity. JAKs are tyrosine kinases that bind to membrane receptors stimulated by inflammatory molecules such as interferon, which, upon activation, phosphorylate STAT transcription factors, which translocate to the nucleus and promote the expression of inflammatory genes. JAK inhibitors block signaling via numerous cytokine and hematopoietic growth factor receptors. Some SLE patients with a *STAT4* risk allele responded better to JAK inhibitors. JAK/STAT signaling plays a fundamental role in metabolic homeostasis, including glucose tolerance and insulin sensitivity, in a cell-specific manner; e.g., stimulation of JAK/STAT3 signaling results in increased translocation of GLUT-4 to the plasma membrane in skeletal muscle cells, and JAK/STAT2 signaling can promote insulin resistance in myocytes. Approved for treatment of RA; clinical trials are ongoing for SLE.	Increase HDL-C and LDL-C in RA and SLE patients. Improve HDL function and increase HDL efflux capacity by increasing the activity of LCAT (enzyme that converts free cholesterol to cholesterol esters and supports cholesterol efflux to lipoproteins). Could alter lipoprotein size and content.	101–106, 108, 226–231
MAPK inhibitors	MAPK inhibitors have pleiotropic effects on immune cell functions and cellular metabolism; this has resulted in multiple failures in clinical trials. The MAPK pathway is stimulated by growth factors, hormones, and inflammatory cytokines, and regulates many cellular functions, including cell cycle, apoptosis, and pro- or antiinflammatory cytokine production such as TNF and IL-1β or IL-10. The MAPKs are split into 3 families: ERK, JNK, and p38 kinase. These regulate cellular function via activation of transcription factors. The MAPK pathway can also be activated by JAK/STAT signaling. Inhibition of p38 by VX-702 is beneficial in RA and animal models of SLE.	MAPK inhibitors could influence lipid metabolism: ERK phosphorylates SREBP-2 (a regulator of cholesterol biosynthesis), and ERK/JNK phosphorylates PPARγ.	96, 112, 113, 115–117, 232–235
NF-κB inhibitors	Iguratimod is an inhibitor of RelA, a component of the NF-κB heterodimer, and is approved for use in patients with RA in China and Japan. Iguratimod reduces inflammatory responses such as T cell differentiation and antibody production by B cells but could also affect the cellular metabolic responses associated with NF-κB signaling. NF-κB is a heterodimer of transcription factors activated by canonical (cytokine receptors, pattern recognition receptors, and T cell and B cell receptors) and non-canonical pathways (ligands for the TNF receptor superfamily, receptor activator of NF-κB, CD40, and B cell–activating factor receptor). Inactivated NF-κB is complexed with the inhibitory protein IκBα in the cytosol; extracellular signals trigger the phosphorylation and dissociation of IκBα from NF-κB, allowing the translocation of activated NF-κB to the nucleus and transcription/promotion of proinflammatory cytokines, chemokines, adhesion molecules, and pathways controlling cell proliferation and differentiation.	Reduce macrophage foam cell formation (lipid accumulation) via reduced expression of lipid transporters (ABCA1/ABCG1) and reduced cholesterol efflux, and increased lipid uptake via scavenger receptors. Antiinflammatory benefits via modulation of cell plasma membrane lipid rafts and reduction of TLR trafficking and signaling.	96, 119–125, 236–239
SYK/BTK inhibitors	Inhibition of SYK/BTK signaling pathways is a potential therapeutic target for RA and SLE owing to their role in B cell activation and proliferation. Multiple BTK inhibitors are currently in clinical trials for AIRDs. SYK and BTK are cytoplasmic nonreceptor tyrosine kinases; SYK/BTK activation leads to downstream signaling through MAPK-, NFAT-, and NF-κB–dependent pathways and has diverse implications including mobilization of intracellular calcium, cell proliferation, differentiation, and regulation of inflammatory gene expression. SYK-mediated signaling is proximal to multiple downstream signaling pathways, including the MAPK and NF-κB pathways. T cells express low levels of SYK and BTK, but increased SYK is found in T cells from SLE patients. SYK is elevated in B cells from patients with RA.	BTK inhibition can inhibit free fatty acid metabolism in chronic lymphocytic leukemia through a reduction of lipoprotein lipase.	96, 128, 129, 240–244

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. ABCA1/ABCG1, ATP-binding cassette transporter A1 and G1; BTK, Bruton's tyrosine kinase; IκBα, nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor-α; LCAT, lecithin-cholesterol acyltransferase; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; SREBP, sterol regulatory element–binding protein; SYK, spleen-associated tyrosine kinase.

effects of MAPKs on immune cell functions and cellular metabolism; this has resulted in multiple failures of MAPK inhibitors in clinical trials (96, 113). Mouse models of kinase deficiency clearly show that interconnected metabolic relationships exist between kinase function and liver-mediated lipid metabolism; altered activity and expression of MAPKs and their inactivating phosphatases are present in models of metabolic disease (114). Notably, downstream insulin signaling stimulates MAPK signaling, ERK can phosphorylate SREBP-2 (a regulator of cholesterol biosynthesis) (115), and ERK/JNK phosphorylates PPARγ (116), linking the MAPK pathway to key regulators of lipid metabolism. The MAPK pathway can also be activated by JAK/STAT signaling (117).

Targeting NF-κB signaling

Aberrant NF-κB signaling is implicated in many inflammatory (RA, SLE) and metabolic (atherosclerosis, obesity, diabetes) diseases (118, 119). Iguratimod, an inhibitor of RelA, a component of the NF-κB heterodimer, is approved for use in patients with RA in China and Japan (refs. 120, 121, and Table 3). Iguratimod could also affect the cellular metabolic responses associated with NF-κB signaling, including macrophage foam cell formation (lipid accumulation), via reduced expression of lipid transporters (ABCA1 and ABCG1), reduced cholesterol efflux, and increased lipid uptake via scavenger receptors (refs. 122, 123, and Figure 1C). Blocking NF-κB signaling could therefore increase cellular cholesterol efflux and reduce lipid uptake, with both atheroprotective implications through reduced foam cell formation (124) and antiinflammatory benefits via modulation of cell plasma membrane lipid rafts and reduction of Toll-like receptor trafficking and signaling (125). Alternatively, inhibition of NF-κB activation in macrophages can increase atherosclerosis in LDLR-deficient mice (126); disparity between studies may be due to different models and experimental approaches, indicating that such off-target effects need to be studied in more detail in patients. Additionally, the atheroprotective transcription factor PPARα, activated by endogenous fatty acid ligands such as arachidonic acid, can suppress entry of NF-κB to the nucleus owing to increased IκBα expression (127), demonstrating the complexity of NF-κB signaling in lipid metabolism.

Targeting SYK/BTK pathways

Finally, SYK/BTK–mediated signaling is proximal to multiple downstream signaling pathways, including the MAPK and NF-κB pathways (ref. 128 and Table 3); BTK inhibition can inhibit free fatty acid metabolism in chronic lymphocytic leukemia through reduction of lipoprotein lipase (129). Furthermore, crosstalk between BTK signaling and bioenergetic stress responses in leukemic B cells suggests that cellular metabolic rewiring could mediate the metabolic effects of these molecules (130). Multiple BTK inhibitors are currently in clinical trials for AIRDs.

Biologics

Biologic therapies are target specific and, despite their eventual catabolism by proteases and complications surrounding anti-drug antibodies, they do not undergo in vivo metabolism within immune cells to elicit their desired effects (ref. 131 and Table 4). Notably, several biologics influence lipid and lipoprotein metabolism, and it is likely that biologics have additional indirect metabolic actions associated with preventing inflammatory cytokines from binding their receptors, as seen with JAK inhibitors (132, 133).

IL-6 receptor antagonists

Tocilizumab and sarilumab inhibit IL-6 receptor binding to IL-6 and block downstream signaling via multiple pathways, including JAK/STAT, p38/JNK, and MAPK (134). Patients with RA are typically characterized by low levels of LDL, potentially due to LDL-C hypercatabolism driven by the IL-6/acute-phase response (85). By blocking hepatic IL-6 signaling, tocilizumab restores LDL-C metabolism and increases serum LDL-C (85, 135, 136). Tocilizumab also increases HDL and triglyceride serum levels in RA patients (137) and promotes HDL cellular cholesterol efflux capacity (ref. 138 and Figure 1C).

TNF inhibitors

Treatment with TNF inhibitors (e.g., etanercept or adalimumab) also increases HDL, total cholesterol, and triglycerides, while the apolipoprotein B/apolipoprotein A1 ratio is decreased and LDL-C levels remain unchanged (139). These effects could reduce CVD risk in RA patients (140), potentially by altering the HDL-associated proteome and improving HDL function, when inflammation is reduced by either adalimumab or abatacept (CTLA-4 fusion protein blocking CD80/CD86 costimulation) (141). Interestingly, adalimumab was associated with higher HDL-associated serotransferrin and immunoglobulin J chain and lower serum amyloid A-I in comparison with patients treated with abatacept (141). It has also been shown that RA patients receiving tocilizumab have a greater increase in LDL-C levels compared with those treated with adalimumab (142), highlighting the differential effects of various biologics on lipid metabolism.

Rituximab

Several studies have reported altered lipid profiles following rituximab (anti-CD20 monoclonal antibody) treatment in AIRDs. In SLE, rituximab reduced triglycerides and resultant atherogenic index of plasma values, likely associated with improvement in disease activity, although reductions in total cholesterol and LDL-C did not reach statistical significance and HDL levels remained stable (143). In contrast, a separate study showed that RA patients treated with rituximab had reduced total cholesterol and HDL levels associated with improved endothelial function and decreased carotid intima-media thickness (144), supporting beneficial metabolic effects. However, another study investigating RA patients responding to rituximab therapy only partially replicated this, showing an increase in total cholesterol and HDL with a paradoxical decreased atherogenic index of plasma and carotid intima-media thickness (145). The disparities between these studies could be dependent on the level of baseline dyslipidemia.

It is plausible that biologic therapies influence systemic lipid metabolism partly via the general dampening of inflammation, particularly considering that the liver is largely responsible for circulating lipoprotein metabolism, as seen in transplant recipients (146). This could also be due to altered hepatic cytokine signaling, as, for example, TNF-α can reduce lipoprotein lipase activity and liver metabolism (147), while in hepatic steatosis IL-1 signaling increased fatty acid synthase expression and triglyceride accumulation (148). Alternatively, in RA, blocking hepatic IL-6 signaling (tocilizumab) restored normal LDL catabolism induced by IL-6 suppression of CYP enzymes. Normalizing CYP enzyme expression could also have a wider effect on cell metabolism generally (85). The effect of anti–IL-17 antibodies (secukinumab) on lipid metabolism remains uncertain, with reports showing increased, unchanged, or reduced HDL and cholesterol levels as well as increased triglyceride levels (149). This uncertainty exists even though IL-17, a proinflammatory cytokine implicated in AIRD and atherosclerosis pathogenesis, is known to affect cholesterol and lipoprotein metabolism (150, 151) and promote foamy macrophage formation (152).

Immune cell lipid metabolism could also be influenced by biologics. Recently, IFNs were shown to have differential effects on membrane cholesterol metabolism in macrophages, including downregulation of cholesterol biosynthesis (153, 154); this effect was not observed with TNF-α, IL-1β, or IL-6, suggesting that new

Table 4. Mechanisms of action of biologic therapies used in AIRDs

Drug	Mechanisms/effects	Effects on lipid metabolism	Refs.
Biologics	Target specific therapies that do not undergo in vivo metabolism and include monoclonal antibodies or fusion proteins against specific immunoregulatory proteins such as proinflammatory cytokines and their receptors — e.g., TNFis; IL-1 receptor; anti–IL-6 receptor and anti–type I IFN receptor antagonists, anti–IL-12/23, and anti–IL-17,; and immune cell receptors (anti-CD20, anti-CD40L, anti–B cell–activating factor, and CTLA-4 fusion protein blocking CD80 and CD86). Block signaling pathways targeted by tsDMARDs including MAPK, NF-κB, and JAK/STAT pathways; e.g., IL-1 and TNF-α stimulate MAPK signaling and cross-activate NF-κB and are blocked by direct TNFis and IL-1 receptor antagonists. Biologics have additional indirect metabolic actions associated with preventing inflammatory cytokines from binding their receptors as with JAK inhibitors.	IL-6 receptor agonists restore LDL-C metabolism and increase serum LDL, increase HDL and triglyceride serum levels in RA patients, and promote HDL cellular cholesterol efflux capacity. TNFis increase HDL, total cholesterol, and triglycerides and decrease apolipoprotein B/apolipoprotein A1. They potentially alter the HDL-associated proteome and improve HDL function — higher HDL-associated serotransferrin and immunoglobulin J chain and lower serum amyloid A-I. In SLE, rituximab reduces triglycerides and had a trend toward lowered total cholesterol and LDL. In RA, rituximab reduces total cholesterol and HDL levels, improves endothelial function, and decreases carotid intima-media thickness. Another study showed increased total cholesterol and HDL and decreased carotid intima-media thickness. Modulation of lipid rafts, potentially by alteration in lipoprotein-mediated cholesterol uptake or efflux, could influence rituximab efficacy. Anti–IL-17 antibodies show increased, unchanged, or reduced HDL and cholesterol levels and increased triglycerides levels.	85, 131–133, 135–139, 141, 143, 144, 149, 155, 245–248

Overview of the mechanisms of action of therapies used for patients with AIRDs and their effect on lipid metabolism pathways. NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; TNFis, TNF inhibitors.

therapies such as anifrolumab (anti–type I IFN receptor antibody) could have effects on both systemic (hepatic) and local (immune cell) lipid metabolism. Changes in immune cell lipid metabolism can also influence cell signaling via changes in lipid rafts (9, 68). By binding membrane CD20, rituximab induces its translocation to lipid rafts, which is crucial, under some conditions, for induction of B cell apoptosis and can be prevented by disruption of lipid rafts by cholesterol depletion (155). However, binding of anti-CD20 antibodies can also trigger antiapoptotic signaling via SYK and AKT pathways, an effect that was also inhibited by cholesterol depletion (156, 157). Thus, modulation of lipid rafts, potentially by alteration of lipoprotein-mediated cholesterol uptake or efflux, could influence drug efficacy. Experimental evidence in cancer immunotherapy shows that inhibition of acetyl-CoA acetyltransferase-1 (ACAT1), an enzyme that increases intracellular esterified cholesterol levels, improves the efficacy of anti–PD-1 therapy in melanoma (158). Reduced cholesterol esterification in CD8+ T cells increased plasma membrane cholesterol levels and subsequent lipid raft–associated T cell receptor clustering and signaling, thereby increasing T cell cytotoxicity against melanoma growth. ACAT inhibition can also boost the antiviral activity of CD8+ T cells against hepatitis B by promoting lipid raft signaling in vitro (159).

Advances supporting metabolism- and inflammation-targeted therapies in AIRDs

Chronic inflammation and dyslipidemia (which can be exacerbated by current therapies) both contribute to increased CVD risk in patients with AIRDs. However, studies show that lipid-lowering drugs (such as statins) are not sufficient to reduce CVD risk in some AIRDs, possibly because they cannot completely restore the antiinflammatory properties of HDL (160, 161). Thus, an unmet clinical need exists for better therapies to address both inflammation and atherosclerosis.

Altered lipid metabolism is frequently associated with the use of nonselective and targeted AIRD treatments. The impact of therapy on lipid profiles can be beneficial, as in the case of hydroxychloroquine, which reduces LDL-C in SLE (63), or lead to new drug-induced dyslipidemia or exacerbate current dyslipidemia associated with AIRD (Tables 1–4) with various clinical outcomes. In the context of high mortality rates associated with CVD in AIRDs, lipid modification therapies are a key cotherapy of interest. Statins are inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, that reduce levels of circulating cholesterol, particularly cholesterol carried in LDL particles. Atorvastatin can reverse tofacitinib-induced elevation of total cholesterol, LDL-C, and triglycerides in patients with RA (107), and patients treated with statins for over 6 months have improved disease activity scores in comparison with conventional RA therapies, supporting a potential beneficial role for statins in patients with active RA (162). Other trials have assessed the use of statins to reduce inflammation. High-dose statins reduced brain atrophy and disability progression in patients with secondary progressive multiple sclerosis in a randomized controlled trial (163, 164). Statins have also been tested in SLE to treat inflammation and dyslipidemia, with mixed outcomes. Some studies show beneficial effects such as improved lipid and inflammatory cytokine levels and reductions in vascular inflammation, atherosclerotic plaque progression, mortality, and morbidity (165–168). However, statins have not met their primary endpoint in clinical trials, including the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial

in children (169) and the Lupus Atherosclerosis Prevention Study (LAPS) in adults (170). Interestingly, although the LAPS 2-year intervention trial did not meet the atherosclerosis primary and secondary endpoints, significant changes in lipid profiles [lipoprotein(a) and total cholesterol] were reported. Difficulties in stratifying patients based on their initial dyslipidemia status as well as their background medication could be the reason for this.

Recent studies of lipoprotein taxonomy in patients with adult and juvenile-onset SLE (171, 172) and multiple sclerosis (173) have highlighted the heterogeneity in patient lipoprotein profiles. Therefore, baseline lipid levels could be important predictors of therapeutic benefit, as has been shown in RA patients treated with tocilizumab and JAK inhibitors, among whom patients with increased lipid levels had a better response to lipid-lowering drugs (107, 135). Other therapies targeting lipid metabolism include reconstituted HDL (shown to reduce plaque in lipid content, macrophage size, and inflammation; ref. 174) and the recently approved statin alternative inclisiran, which increases LDLR levels in the liver (by inhibiting proprotein convertase subtilisin/kexin type 9, the enzyme responsible for LDLR inhibition), thereby reducing LDL-C in the blood by up to 50%, similarly to high-dose statins (175). In the future, new lipid-modifying drugs could be used as an alternative to, or in combination with, statins for patients with AIRDs and dyslipidemia not controlled by conventional treatment and at high risk of cardiovascular events, particularly in those on antiinflammatory treatments that exacerbate dyslipidemia as discussed above.

Some immune receptors that reside in lipid rafts are targeted by AIRD treatments — including CD20 targeted by rituximab (155), CD80/CD86 targeted by abatacept (141), and IL-6R targeted by tocilizumab (176) — suggesting that lipid modification could potentially alter the efficiency of these therapies by regulating membrane turnover of these receptor targets. Some biologic agents require intact lipid rafts to exert their therapeutic function, e.g., rituximab (155–157). Furthermore, pharmacologic inhibition of lipid raft components (cholesterol and glycosphingolipids) using statins and glycolipid synthase inhibitors (N-butyldeoxynojirimycin) restored defective lipid raft levels and normalized in vitro function in CD4$^+$ T cells from patients with SLE. This included T cell receptor signaling and function and anti-dsDNA antibody production by autologous B cells (10, 177). Interestingly, elevated glycosphingolipid levels in SLE T cells were associated with the increased expression of the LXR master lipid transcriptional regulator, which directly modulates enzymes involved in glycosphingolipid synthesis (9). Whether supplementation with compounds targeting LXR could further modulate lipid rafts and AIRD drug efficacies remains to be explored.

In some circumstances, the dose of lipid-modifying therapies must be adjusted when they are used in combination with AIRD therapies. Tocilizumab normalizes CYP enzyme expression and increases LDL-C; therefore patients on statin cotherapy may require an increased dose to maintain therapeutic lipid-lowering benefits (135). Cyclosporin can also affect the pharmacokinetics of statins through the inhibition of both organic anion transporter polypeptide-1B1 and CYP3A4 (178). Also, lipids including HDL play an important role as S1P chaperones; therefore, alterations in lipoprotein metabolism could influence the efficacy of drugs modulating the S1P pathway (e.g., fingolimod), which are now used in multiple sclerosis and being investigated in AIRDs (34, 179).

Dietary patterns also modify inflammation; those with a higher inflammatory potential are significantly associated with unfavorable lipid profiles and a higher incidence of CVD (180). Despite these observations, the relationship between nutrition and inflammation in AIRDs is not well established. Oral lipid supplements may aid the effectiveness of conventional therapies, such as essential fatty acid supplementation to increase STM levels; these have been linked to decreased joint pain and predict DMARD responsiveness in RA (31). Dietary polyunsaturated fatty acids can also inhibit ferroptosis (181) and incorporate into T cell membranes, thus altering plasma membrane phospholipid expression and the localization of immunogenic receptors such as IL-2 receptor and Fc receptors into lipid raft microdomains (182). Dietary intervention to alter blood lipids can be beneficial in SLE and RA and reduce disease activity scores (183–185). Increased dietary intake of omega-3 fatty acids increased HDL and reduced triglycerides in juvenile-onset SLE (183, 186) and increased HDL and reduced VLDL in adult SLE (187). Thus omega-3 dietary supplements could be promising therapeutic options for some patients. In contrast, a randomized controlled trial of dietary restrictive patterns reduced weight and fatigue in adults with SLE, but did not affect disease activity or cardiovascular parameters including lipid profiles and inflammatory markers (188).

Conclusion

Understanding how lipid metabolism influences immune responses and the effect of both conventional and new therapies on lipid metabolism is an ongoing challenge but could identify new ways to target AIRDs. Better control of inflammation using optimal combinations of immunosuppressive treatments, as shown in inflammatory bowel disease (189), could lead to an improved metabolic/lipid profile in AIRDs. Improved monitoring of pro-/antiinflammatory lipoprotein fractions using a granular lipoprotein taxonomy approach and improved CVD risk stratification biomarkers (171, 172), rather than total HDL/LDL levels, could improve targeted patient management. This is relevant since statins do not completely normalize proinflammatory HDL fractions (160). Such improved monitoring could enable novel combination interventions, such as nonspecific dietary intervention with specific lipid lowering and targeted antiinflammatory therapy. Finally, the clinical relevance of metabolic/lipid biomarkers in AIRDs needs to be explored in long-term studies to capture the long-term toxicity of combined therapies as well as their impact on cardiovascular events.

Acknowledgments

REVIEW SERIES: IMMUNOMETABOLISM

The Journal of Clinical Investigation

Address correspondence to: Elizabeth C. Jury, Centre for Rheumatology Research, University College London, 4th Floor Rayne Institute, 5 University Street, London WC1E 6JF, United Kingdom. Phone: 44.0.20.3108.2161; Email: e.jury@ucl.ac.uk.

1. Rhoads JP, et al. Fine tuning of immunometabolism for the treatment of rheumatic diseases. *Nat Rev Rheumatol*. 2017;13(5):313–320.

2. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. *Trends Immunol*. 2012;33(4):168–173.

3. Waters LR, et al. Initial B cell activation induces metabolic reprogramming and mitochondrial remodeling. *iScience*. 2018;5:99–109.

4. Galván-Peña S, O'Neill LAJ. Metabolic reprograming in macrophage polarization. *Front Immunol*. 2014;5:420.

5. Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. *Nat Rev Rheumatol*. 2016;12(3):169–182.

6. Han X. Lipidomics for studying metabolism. *Nat Rev Endocrinol*. 2016;12(11):668–679.

7. Jury EC, et al. Lipid rafts in T cell signalling and disease. *Semin Cell Dev Biol*. 2007;18(5):608–615.

8. Pierce SK. Lipid rafts and B-cell activation. *Nat Rev Immunol*. 2002;2(2):96–105.

9. Waddington KE, et al. LXR directly regulates glycosphingolipid synthesis and affects human CD4+ T cell function. *Proc Natl Acad Sci U S A*. 2021;118(21):e2017394118.

10. McDonald G, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. *J Clin Invest*. 2014;124(2):712–724.

11. Flores-Borja F, et al. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. *Arthritis Rheum*. 2007;56(1):291–302.

12. Luo J, et al. Mechanisms and regulation of cholesterol homeostasis. *Nat Rev Mol Cell Biol*. 2020;21(4):225–245.

13. Hahn BH, et al. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. *J Autoimmun*. 2007;28(2-3):69–75.

14. Myasoedova E, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. *Ann Rheum Dis*. 2011;70(3):482–487.

15. McMahon M, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. *Arthritis Rheum*. 2009;60(8):2428–2437.

16. Ardoin S, et al. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. *Lupus*. 2007;16(8):618–626.

17. Szabo MZ, et al. Dyslipidemia in systemic lupus erythematosus. *Immunol Res*. 2017;65(2):543–550.

18. Wu T, et al. Metabolic disturbances associated with systemic lupus erythematosus. *PLoS One*. 2012;7(6):e37210.

19. Charles-Schoeman C, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. *Arthritis Rheum*. 2009;60(10):2870–2879.

20. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. *Nat Rev Immunol*. 2015;15(8):511–523.

21. Norris PC, et al. Phospholipase A2 regulates eicosanoid class switching during inflammasome activation. *Proc Natl Acad Sci U S A*. 2014;11(35):12746–12751.

22. Wang B, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. *Signal Transduct Target Ther*. 2021;6(1):94.

23. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. *Trends Endocrinol Metab*. 2012;23(7):351–363.

24. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. *Nat Rev Immunol*. 2002;2(10):748–759.

25. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. *Annu Rev Biochem*. 2008;77:289–312.

26. Ricote M, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature*. 1998;391(6662):79–82.

27. Gervois P, et al. Regulation of lipid and lipoprotein metabolism by PPAR activators. *Clin Chem Lab Med*. 2000;38(1):3–11.

28. Buckley CD, et al. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. *Immunity*. 2014;40(3):315–327.

29. Barden AE, et al. Specialised pro-resolving mediators of inflammation in inflammatory arthritis. *Prostaglandins Leukot Essent Fatty Acids*. 2016;107:24–29.

30. Arnardottir HH, et al. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation. *J Immunol*. 2016;197(6):2362–2368.

31. Gomez EA, et al. Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis. *Nat Commun*. 2020;11(1):13.

32. Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. *Science*. 2019;366(6463):eaar5551.

33. Galvani S, et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. *Sci Signal*. 2015;8(389):ra79.

34. Pérez-Jeldres T, et al. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. *Drugs*. 2021;81(9):985–1002.

35. Jiang X, et al. Ferroptosis: mechanisms, biology and role in disease. *Nat Rev Mol Cell Biol*. 2021;22(4):266–282.

36. Chen X, et al. Ferroptosis in infection, inflammation, and immunity. *J Exp Med*. 2021;218(6):e20210518.

37. Wlazlo E, et al. Iron metabolism: an under investigated driver of renal pathology in lupus nephritis. *Front Med (Lausanne)*. 2021;8:643686.

38. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. *Semin Arthritis Rheum*. 1997;26(6 suppl 1):2–10.

39. Seppala E, et al. Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. *Scand J Rheumatol*. 1990;19(1):71–75.

40. van der Heijde D, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum*. 2005;52(4):1205–1215.

41. Bhala N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*. 2013;382(9894):769–779.

42. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. *Nat Rev Drug Discov*. 2006;5(1):75–86.

43. Schonbeck U, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. *Am J Pathol*. 1999;155(4):1281–1291.

44. Thiemermann C. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. *Br J Pharmacol*. 2004;141(1):1–3.

45. Tilley SL, et al. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest*. 2001;108(1):15–23.

46. Akman B, et al. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids. *Transplant Proc*. 2007;39(1):135–137.

47. Panoulas V, Kitas GD. Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. *Expert Rev Clin Pharmacol*. 2020;13(6):605–613.

48. van der Goes MC, et al. The value of glucocorticoid co-therapy in different rheumatic diseases — positive and adverse effects. *Arthritis Res Ther*. 2014;16(suppl 2):S2.

49. Petta I, et al. Risks and benefits of corticosteroids in arthritic diseases in the clinic. *Biochem Pharmacol*. 2019;165:112–125.

50. Petri M, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med*. 1992;93(5):513–519.

51. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. *Mol Cell Endocrinol*. 2007;275(1-2):43–61.

52. Radhakutty A, et al. Effects of prednisolone on energy and fat metabolism in patients with rheumatoid arthritis: tissue-specific insulin resistance with commonly used prednisolone doses. *Clin Endocrinol (Oxf)*. 2016;85(5):741–747.

53. Liu DR, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin*

Immunol. 2013;9(1):25.

54. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. *Can J Cardiol*. 2000;16(4):505–511.

55. Garcia-Gomez C, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. *Eur J Clin Invest*. 2008;38(9):686–692.

56. Ettinger WH, et al. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. *Atherosclerosis*. 1987;63(2-3):167–172.

57. Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis*. 2017;76(1):17–28.

58. Ben-Zvi I, et al. Hydroxychloroquine: from malaria to autoimmunity. *Clin Rev Allergy Immunol*. 2012;42(2):145–153.

59. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol*. 2020;16(3):155–166.

60. Gómez-Guzmán M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. *Hypertension*. 2014;64(2):330–337.

61. Rahman R, et al. The effects of hydroxychloroquine on endothelial dysfunction. *Pregnancy Hypertens*. 2016;6(4):259–262.

62. Espinola RG, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. *Thromb Haemost*. 2002;87(03):518–522.

63. Cairoli E, et al. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. *Lupus*. 2012;21(11):1178–1182.

64. Rempenault C, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Ann Rheum Dis*. 2018;77(1):98–103.

65. Dutta S, Ahmad Y. The efficacy and safety of tacrolimus in rheumatoid arthritis. *Ther Adv Musculoskelet Dis*. 2011;3(6):283–291.

66. Lane JCE, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. *Lancet Rheumatol*. 2020;2(11):e698–e711.

67. Fantini J, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. *Int J Antimicrob Agents*. 2020;55(5):105960.

68. Miguel L, et al. Primary human CD4+ T cells have diverse levels of membrane lipid order that correlate with their function. *J Immunol*. 2011;186(6):3505–3516.

69. Höcherl K, et al. Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. *J Am Soc Nephrol*. 2002;13(10):2427–2436.

70. Chakkera H, et al. Negative cardiovascular consequences of small molecule immunosuppressants. *Clin Pharmacol Ther*. 2017;102(2):269–276.

71. Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity-what the FK? *Adv Chronic Kidney Dis*. 2020;27(1):56–66.

72. Gueguen Y, et al. Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. *Basic Clin Pharmacol Toxicol*. 2007;100(6):392–397.

73. Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2021;397(10289):2070–2080.

74. de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. *Mayo Clin Proc*. 1988;63(10):1012–1021.

75. Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. *Nat Rev Rheumatol*. 2020;16(3):167–178.

76. Zheng ZH, et al. Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ. *Eur J Pharmacol*. 2011;658(1):1–8.

77. Heischmann S, et al. The immunosuppressant mycophenolic acid alters nucleotide and lipid metabolism in an intestinal cell model. *Sci Rep*. 2017;7(1):45088.

78. Nam HJ, et al. Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma. *iScience*. 2021;24(3):102238.

79. Krol SK, et al. Comprehensive review on betulin as a potent anticancer agent. *Biomed Res Int*. 2015;2015:584189.

80. Tang JJ, et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. *Cell Metabolism*. 2011;13(1):44–56.

81. Oishi Y, et al. SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism. *Cell Metab*. 2017;25(2):412–427.

82. Lee JH, et al. SREBP-1a-stimulated lipid synthesis is required for macrophage phagocytosis downstream of TLR4-directed mTORC1. *Proc Natl Acad Sci U S A*. 2018;115(52):E12228–E12234.

83. Navarro-Millán I, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. *Arthritis Rheum*. 2013;65(6):1430–1438.

84. Watanabe J, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. *Arthritis Rheum*. 2012;64(6):1828–1837.

85. Robertson J, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. *Ann Rheum Dis*. 2017;76(11):1949–1952.

86. Micha R, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. *Am J Cardiol*. 2011;108(9):1362–1370.

87. Tam H-W, et al. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. *Int J Rheum Dis*. 2017;20(3):363–370.

88. Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. *Br J Rheumatol*. 1995;34:7–15.

89. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. *Clin Pharmacokinet*. 1985;10(4):285–302.

90. Dirlik M, et al. Effects of sulfasalazine on lipid peroxidation and histologic liver damage in a rat model of obstructive jaundice and obstructive jaundice with lipopolysaccharide-induced sepsis. *Curr Ther Res Clin Exp*. 2009;70(4):299–315.

91. MacMullan PA, et al. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. *Clin Rheumatol*. 2016;35(2):447–455.

92. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. *Ann Rheum Dis*. 2000;59(11):841–849.

93. Guleria A, et al. NMR-based serum metabolomics reveals reprogramming of lipid dysregulation following cyclophosphamide-based induction therapy in lupus nephritis. *J Proteome Res*. 2018;17(7):2440–2448.

94. Iqubal A, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. *Life Sci*. 2019;218:112–131.

95. Zhang T, Mohan C. Caution in studying and interpreting the lupus metabolome. *Arthritis Res Ther*. 2020;22(1):172.

96. Massalska M, et al. Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: latest updates and potential strategy for fighting COVID-19. *Cells*. 2020;9(8):21.

97. Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. *Clin Immunol*. 2013;148(3):359–368.

98. Thompson C, et al. Anti cytokine therapy in chronic inflammatory arthritis. *Cytokine*. 2016;86:92–99.

99. Tang GL, et al. Inhibition of JNK activation through NF-kappa B target genes. *Nature*. 2001;414(6861):313–317.

100. McGarry T, et al. JAK/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis. *Arthritis Rheumatol*. 2018;70(12):1959–1970.

101. Lee EB, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*. 2014;370(25):2377–2386.

102. Souto A, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. *Arthritis Rheumatol*. 2015;67(1):117–127.

103. Charles-Schoeman C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. *Arthritis Rheumatol*. 2015;67(3):616–625.

104. Qiu CF, et al. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Lipids Health Dis*. 2019;18(1):11.

105. Wallace DJ, et al. Baricitinib for systemic lupus

erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet*. 2018;392(10143):222–231.

106. Hasni SA, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. *Nat Commun*. 2021;12(1):3391.

107. McInnes IB, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. *Ann Rheum Dis*. 2014;73(1):124–131.

108. Charles-Schoeman C, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. *Semin Arthritis Rheum*. 2016;46(1):71–80.

109. Samuelson BT, et al. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. *Blood Coagul Fibrinolysis*. 2016;27(6):648–652.

110. Cohen SB. JAK inhibitors and VTE risk: how concerned should we be? *Nat Rev Rheumatol*. 2021;17(3):133–134.

111. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Updated September 16, 2021. Accessed October 19, 2021.

112. Hernandez-Florez D, Valor L. Protein-kinase inhibitors: a new treatment pathway for autoimmune and inflammatory diseases? *Reumatol Clin*. 2016;12(2):91–99.

113. Damjanov N. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis results of two randomized, double-blind, placebo-controlled clinical studies. *Arthritis Rheum*. 2009;60(5):1232–1241.

114. Lawan A, Bennett AM. Mitogen-activated protein kinase regulation in hepatic metabolism. *Trends Endocrinol Metab*. 2017;28(12):868–878.

115. Kotzka J, et al. Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding protein-2 at serine residues 432 and 455 in vivo. *J Biol Chem*. 2004;279(21):22404–22411.

116. Hu ED, et al. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma. *Science*. 1996;274(5295):2100–2103.

117. Malemud CJ. Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. *Pharmaceuticals (Basel)*. 2010;3(5):1446–1455.

118. Pai S, Thomas R. Immune deficiency or hyperactivity-Nf-κb illuminates autoimmunity. *J Autoimmun*. 2008;31(3):245–251.

119. Baker RG, et al. NF-κB, inflammation, and metabolic disease. *Cell Metab*. 2011;13(1):11–22.

120. Xie SS, et al. Iguratimod as a new drug for rheumatoid arthritis: current landscape. *Front Pharmacol*. 2020;11:73.

121. Hara M, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind,

placebo-controlled trial. *Mod Rheumatol*. 2014;24(3):410–418.

122. Yu XH, et al. Interleukin-18 and interleukin-12 together downregulate ATP-binding cassette transporter A1 expression through the interleukin-18R/nuclear factor-κB signaling pathway in THP-1 macrophage-derived foam cells. *Circ J*. 2012;76(7):1780–1791.

123. Yu XH, et al. Nuclear factor-κ B activation as a pathological mechanism of lipid metabolism and atherosclerosis. *Adv Clin Chem*. 2015;70:1–30.

124. Ferreira V, et al. Macrophage-specific inhibition of NF-κ B activation reduces foam-cell formation. *Atherosclerosis*. 2007;192(2):283–290.

125. Zhu XW, et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. *J Lipid Res*. 2010;51(11):3196–3206.

126. Kanters E, et al. Inhibition of NF-κ B activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. *J Clin Invest*. 2003;112(8):1176–1185.

127. Soskic SS, et al. Peroxisome proliferator-activated receptors and atherosclerosis. *Angiology*. 2011;62(7):523–534.

128. Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. *Cold Spring Harb Perspect Biol*. 2011;3(3):a002352.

129. Rozovski U, et al. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2018;59(11):2686–2691.

130. Sharif-Askari B, et al. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. *Sci Rep*. 2019;9(1):11069.

131. Strand V, et al. Immunogenicity of biologic agents in rheumatology. *Nat Rev Rheumatol*. 2021;17(2):81–97.

132. Bishop EL, et al. Control of T cell metabolism by cytokines and hormones. *Front Immunol*. 2021;12:15.

133. Shi J, et al. Cytokines and abnormal glucose and lipid metabolism. *Front Endocrinol (Lausanne)*. 2019;10:16.

134. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. *Am J Health Syst Pharm*. 2008;65(15):1413–1418.

135. Dhillon S. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. *BioDrugs*. 2014;28(1):75–106.

136. McInnes IB, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis*. 2015;74(4):694–702.

137. Giles JT, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. *Arthritis Rheumatol*. 2020;72(1):31–40.

138. Pierini FS, et al. Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study. *Rheumatol Ther*. 2021;8(2):803–815.

139. Daien CI, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. *Ann Rheum Dis*. 2012;71(6):862–868.

140. Dixon WG, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 2007;56(9):2905–2912.

141. Charles-Schoeman C, et al. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. *Atherosclerosis*. 2018;275:107–114.

142. Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*. 2013;381(9877):1541–1550.

143. Fernandez-Nebro A, et al. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). *Lupus*. 2014;23(10):1014–1022.

144. Kerekes G, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. *Clin Rheumatol*. 2009;28(6):705–710.

145. Novikova DS, et al. The effects of rituximab on lipids, arterial stiffness and carotid intima-media thickness in rheumatoid arthritis. *J Korean Med Sci*. 2016;31(2):202–207.

146. Huang HT, et al. Predicting dyslipidemia after liver transplantation: a significant role of recipient metabolic inflammation profile. *World J Gastroenterol*. 2020;26(19):2374–2387.

147. McDevitt H, et al. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. *Arthritis Res*. 2002;4:S141–S152.

148. Negrin KA, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. *PLoS One*. 2014;9(9):15.

149. Wang HN, Huang YH. Changes in metabolic parameters in psoriatic patients treated with secukinumab. *Ther Adv Chronic Dis*. 2020;11:2040622320944777.

150. Varshney P, et al. Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. *Sci Rep*. 2016;6(1):19295.

151. Huang LH, et al. Interleukin-17 drives interstitial entrapment of tissue lipoproteins in experimental psoriasis. *Cell Metab*. 2019;29(2):475–487.

152. Yu X-H, et al. Interleukin-17A in lipid metabolism and atherosclerosis. *Clin Chim Acta*. 2014;431:33–39.

153. Zhou QD, et al. Interferon-mediated reprogramming of membrane cholesterol to evade bacterial toxins. *Nat Immunol*. 2020;21(7):746–755.

154. Blanc M, et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. *PLoS Biol*. 2011;9(3):19.

155. Janas E, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. *Clin Exp Immunol*. 2005;139(3):439–446.

156. Nozaki Y, et al. Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels. *Exp Hematol*. 2013;41(8):687–696.

157. Glennie MJ, et al. Mechanisms of killing by anti-

CD20 monoclonal antibodies. *Mol Immunol*. 2007;44(16):3823–3837.

158. Yang W, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. *Nature*. 2016;531(7596):651–655.

159. Schmidt NM, et al. Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. *Nat Commun*. 2021;12(1):2814.

160. Fogelman AM. When good cholesterol goes bad. *Nat Med*. 2004;10(9):902–903.

161. Ansell BJ, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. *Circulation*. 2003;108(22):2751–2756.

162. Das S, et al. Outcome of rheumatoid arthritis following adjunct statin therapy. *Indian J Pharmacol*. 2015;47(6):605–609.

163. Chataway J, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet*. 2014;383(9936):2213–2221.

164. Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. *Ann Neurol*. 2006;60(1):45–55.

165. Yu HH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. *Atherosclerosis*. 2015;243(1):11–18.

166. Ruiz-Limon P, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. *Ann Rheum Dis*. 2015;74(7):1450–1458.

167. Aikawa M, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. *Circulation*. 2001;103(2):276–283.

168. Waehre T, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. *Circulation*. 2004;109(16):1966–1972.

169. Schanberg LE, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. *Arthritis Rheum*. 2012;64(1):285–296.

170. Petri MA, et al. Lupus Atherosclerosis Prevention Study (LAPS). *Ann Rheum Dis*. 2011;70(5):760–765.

171. Coelewij L, et al. Serum metabolomic signatures can predict subclinical atherosclerosis in patients with systemic lupus erythematosus. *Arterioscler Thromb Vasc Biol*. 2021;41(4):1446–1458.

172. Robinson GA, et al. Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. *EBioMedicine*. 2021;65:103243.

173. Waddington KE, et al. Using serum metabolomics to predict development of anti-drug antibodies in multiple sclerosis patients treated with IFNβ. *Front Immunol*. 2020;11:1527.

174. Shaw JA, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. *Circ Res*. 2008;103(10):1084–1091.

175. Ray KK, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*. 2020;382(16):1507–1519.

176. Schmidt-Arras D, Rose-John S. Endosomes as signaling platforms for IL-6 family cytokine receptors. *Front Cell Dev Biol*. 2021;9:688314.

177. Jury EC, et al. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. *J Immunol*. 2006;177(10):7416–7422.

178. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol Ther*. 2006;112(1):71–105.

179. Blaho VA, et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. *Nature*. 2015;523(7560):342–346.

180. Li J, et al. Dietary inflammatory potential and risk of cardiovascular disease among men and women in the U.S. *J Am Coll Cardiol*. 2020;76(19):2181–2193.

181. Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell*. 2017;171(2):273–285.

182. Fan YY, et al. Dietary docosahexaenoic acid suppresses T cell protein kinase C theta lipid raft recruitment and IL-2 production. *J Immunol*. 2004;173(10):6151–6160.

183. da Silva SGL, et al. The effect of nutritional intervention on the lipid profile and dietary intake of adolescents with juvenile systemic lupus erythematosus: a randomized, controlled trial. *Lupus*. 2018;27(5):820–827.

184. Walton AJ, et al. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. *Ann Rheum Dis*. 1991;50(7):463–466.

185. Philippou E, et al. Rheumatoid arthritis and dietary interventions: systematic review of clinical trials. *Nutr Rev*. 2021;79(4):410–428.

186. Ilowite NT, et al. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. *J Rheumatol*. 1995;22(7):1347–1351.

187. Clark WF, et al. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. *Kidney Int*. 1989;36(4):653–660.

188. Davies RJ, et al. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. *Lupus*. 2012;21(6):649–655.

189. Hirten RP, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. *Clin Gastroenterol Hepatol*. 2018;16(9):1374–1384.

190. Mardini IA, FitzGerald GA. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. *Mol Interv*. 2001;1(1):30–38.

191. Crofford LJ, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. *J Clin Invest*. 1994;93(3):1095–1101.

192. Rose JW, et al. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. *J Neuroimmunol*. 2004;149(1-2):40–49.

193. Xu LT, et al. Human lupus T cells resist inactivation and escape death by upregulating COX-2. *Nat Med*. 2004;10(4):411–415.

194. Petta I, et al. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases. *Microbiol Mol Biol Rev*. 2016;80(2):495–522.

195. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. *Immunol Allergy Clin North Am*. 2005;25(3):451–468.

196. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. *Int J Dermatol*. 2010;49(3):239–248.

197. Mauthe M, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy*. 2018;14(8):1435–1455.

198. Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. *APMIS*. 2002;110(6):481–489.

199. Lotteau V, et al. Intracellular transport of class II MHC molecules directed by invariant chain. *Nature*. 1990;348(6302):600–605.

200. Kuznik A, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. *J Immunol*. 2011;186(8):4794–4804.

201. An J, et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. *Annu Rev Med*. 2017;68:317–330.

202. Vaeth M, et al. Store-operated Ca^{2+} entry controls clonal expansion of T cells through metabolic reprogramming. *Immunity*. 2017;47(4):664–679.

203. Gwack Y, et al. Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes. *Cell Calcium*. 2007;42(2):145–156.

204. Park YJ, et al. The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. *Front Immunol*. 2020;11:14.

205. Wu QH, Kuca K. Metabolic pathway of cyclosporine a and its correlation with nephrotoxicity. *Curr Drug Metab*. 2019;20(2):84–90.

206. Ransom JT. Mechanism of action of mycophenolate mofetil. *Ther Drug Monit*. 1995;17(6):681–684.

207. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology*. 2000;47(2):85–118.

208. Suthanthiran M, Strom TB. Immunoregulatory drugs: mechanistic basis for use in organ transplantation. *Pediatr Nephrol*. 1997;11(5):651–657.

209. Vanscoik KG, et al. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. *Drug Metab Rev*. 1985;16(1-2):157–174.

210. VanOs EC, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. *Gut*. 1996;39(1):63–68.

211. Baugh CM, et al. Polygammaglutamyl metabolites of methotrexate. *Biochem Biophys Res Commun*. 1973;52(1):27–34.

212. Cutolo M, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. *Ann Rheum Dis*. 2001;60(8):729–735.

213. Gubner R, et al. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. *Am J Med Sci*.

1951;221(2):176–182.

214. Bedoui Y, et al. Methotrexate an old drug with new tricks. *Int J Mol Sci*. 2019;20(20):5023.

215. Brown PM, et al. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol*. 2016;12(12):731–742.

216. Bouma MG, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. *J Immunol*. 1994;153(9):4159–4168.

217. Pirkmajer S, et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. *Diabetes*. 2015;64(2):360–369.

218. Solomon DH, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. *JAMA*. 2011;305(24):2525–2531.

219. Toms TE, et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an anti-inflammatory effect? A cross sectional study. *Arthritis Res Ther*. 2009;11(4):R110.

220. Rozman B, et al. Leflunomide and hypertension. *Ann Rheum Dis*. 2002;61(6):567–569.

221. Dong GF, et al. Effect of leflunomide on the abnormal expression of lipid rafts and F-actin in B lymphocytes from patients with systemic lupus erythematosus. *J Immunol Res*. 2015;2015:832916.

222. Hipkens JH, et al. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. *Cancer Res*. 1981;41(9):3571–3583.

223. Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. *Cancer Chemother Pharmacol*. 2016;78(4):661–671.

224. Jones RJ, et al. Assessment of aldehyde dehydrogenase in viable cells. *Blood*. 1995;85(10):2742–2746.

225. Thomas SS, et al. Immunosuppressives: cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil. In: Hochberg MC, et al., eds. *Rheumatology*. 6th ed. Mosby; 2015:459–467.

226. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. *Immunity*. 2012;36(4):542–550.

227. Dodington DW, et al. JAK/STAT — emerging players in metabolism. *Trends Endocrinol Metab*. 2018;29(1):55–65.

228. Abbott MJ, et al. IL-15 activates the Jak3/STAT3 signaling pathway to mediate glucose uptake in skeletal muscle cells. *Front Physiol*. 2017;31:1.

229. Grzelkowska-Kowalczyk K, Wieteska-Skrzeczynska W. Treatment with IFN-gamma prevents insulin-dependent PKB, p70(S6k) phosphorylation and protein synthesis in mouse C2C12 myogenic cells. *Cell Biol Int*. 2010;34(1):117–124.

230. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. *Rheumatology (Oxford)*. 2019;58(suppl 1):i17–i26.

231. Kahl L, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. *Lupus*. 2016;25(13):1420–1430.

232. Schett G, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. *Arthritis Rheum*. 2000;43(11):2501–2512.

233. Lopez-Santalla M, et al. Tyr(323)-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity. *Arthritis Rheum*. 2011;63(7):1833–1842.

234. Cully M, et al. A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1. *Mol Cell Biol*. 2010;30(2):481–495.

235. Carr EL, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. *J Immunol*. 2010;185(2):1037–1044.

236. Yu H, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. *Signal Transduct Target Ther*. 2020;5(1):209.

237. Marok R, et al. Activation of the transcription factor nuclear factor-kappa B in human inflamed synovial tissue. *Arthritis Rheum*. 1996;39(4):583–591.

238. Fu LC, et al. BAFF-R promotes cell proliferation and survival through interaction with IKK beta and NF-kappa B/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. *Blood*. 2009;113(19):4627–4636.

239. Xu YZ, et al. Regulatory effect of iguratimod on the balance of th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. *Mediators Inflamm*. 2015;2015:13.

240. Lv JH, et al. Development of bruton's tyrosine kinase inhibitors for rheumatoid arthritis. *Curr Med Chem*. 2018;25(42):5847–5859.

241. Iwata S, et al. Activation of Syk-Btk signal in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. *Arthritis Rheumatol*. 2015;67(1):63–72.

242. Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. *Autoimmunity*. 2010;43(1):48–55.

243. Tan SL, et al. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. *Pharmacol Ther*. 2013;138(2):294–309.

244. Palacios EH, Weiss A. Distinct roles for Syk and ZAP-70 during early thymocyte development. *J Exp Med*. 2007;204(7):1703–1715.

245. Strand V, et al. Biologic therapies in rheumatology: lessons learned, future directions. *Nat Rev Drug Discov*. 2007;6(1):75–92.

246. Park SH. Biologic therapies for the treatment of systemic lupus erythematosus. *J Korean Med Assoc*. 2021;64(2):109–115.

247. Gabay C, et al. IL-1 pathways in inflammation and human diseases. *Nat Rev Rheumatol*. 2010;6(4):232–241.

248. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. *Rheumatology (Oxford)*. 2015;54(12):2134–2144.